Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06247826
Recruiting Not applicable

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

NCT06247826 · tracked via the Priya Life Science France tracker
Sponsor
Groupe Francais De Pneumo-Cancerologie
Phase
Not applicable
Started
2024-01-15
Last updated
2026-04-29

Condition(s) studied

Non-small Cell Lung CancerEGFR Exon 20 Insertion Mutation

Investigational drug(s) / intervention(s)

Blood sampling

Blood sampling: Blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis.

Study summary

The goal of this prospective, interventional study is to evaluate the mechanisms of acquired resistance to amivantamab monotherapy in patients with advanced NSCLC with EGFR ins20. The main question it aims to answer is:

What are the mechanisms of acquired resistance to amivantamab monotherapy in this population of patients ? How anticipate the efficacy of subsequent systemic therapies ?

After this information session, the participant will be asked to sign the study informed consent. A blood samples (2\*10 mL on ethylenediaminetetraacetic acid (EDTA)) will be taken at time of disease progression and will be sent for central liquid biopsy ctDNA analysis. If available, tumor tissue will also be sent for DNA NGS analysis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All patients with advanced NSCLC with EGFR ins20 receiving amivantamab as monotherapy in France under ATU or EAP; * Age ≥ 18 years; * Histologically confirmed advanced NSCLC (metastatic or locally advanced unresectable and not suitable for definitive radiotherapy) with EGFR ins20; * Patients included will be required to sign an informed consent form to collect blood samples (liquid biopsy) and tissue biopsy when available at progression on amivantamab; * Confirmed progression on amivantamab according to RECIST 1.1; * Patient enrolled in the french National Health Insurance program or with a third- party payer. Exclusion Criteria: * Patients receiving amivantamab in combination with another therapy; * Patients who do not consent to liquid biopsy at progression.

Primary outcome measure(s)

Trial sites (18)

FacilityCityRegionStatus
Oncologie Polyclinique Bordeaux Nord Aquitaine Bordeaux France Not Yet Recruiting
Centre Hospitalier du Morvan Brest France Recruiting
Pneumologie Centre Hospitalier Intercommunal de Créteil Créteil France Recruiting
Oncologie, CLCC Dijon Dijon France Not Yet Recruiting
Pneumologie, CHU Grenoble Grenoble France Recruiting
Pneumologie CH Le Mans France Not Yet Recruiting
Oncologie thoracique Hôpital Nord Marseille France Recruiting
Oncologie, Centre Antoine Lacassagne Nice France Withdrawn
Oncologie Institut Curie Paris France Not Yet Recruiting
Hôpital Cochin Paris France Recruiting
Pneumologie, Hôpital Tenon Paris France Recruiting
Pneumologie Centre Hospitalier Pau France Not Yet Recruiting
Pneumologie CHI Cornouaille Quimper France Not Yet Recruiting
Hôpital Charles Nicolle Rouen France Recruiting
CHU La Réunion Site Nord Saint-Denis France Recruiting
CHU Hôpital Nord Saint-Etienne France Recruiting
CH Bretagne Atlantique Vannes France Recruiting
Pneumologie, Hôpital Mutualiste Resamut Villeurbanne France Not Yet Recruiting

More Groupe Francais De Pneumo-Cancerologie trials in France

Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib Recruiting
Observational Prospective Study of Quality of Life in Unresectable TNM Stage III NSCLC (OBSTINATE) Active, not recruiting
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC Recruiting

Other trials for the same condition

Is 3D Modeling From Non-contrast CT Accurate for Minimally Invasive Lung Segmentectomies ? Starting soon
Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours Recruiting
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer Active, not recruiting
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) Active, not recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06247826 on ClinicalTrials.gov ↗ ← All trials in France